Lex

Eli Lilly Alzheimer’s hopes overdone?

Shares in Eli Lilly had already risen 26% ahead of an announcement today about its hopes for its Alzheimer’s treatment. Lex's Richard Stovin-Bradford and Alan Livsey discuss whether the stock climb is overdone.